LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that it has met its enrollment target of 330 patients in U.S. centers for its Phase 2b trial of PRX-00023 in Major Depressive Disorder (MDD). As a result of this rapid enrollment, EPIX expects to announce results of this trial in the first quarter of 2008. Further, EPIX has completed enrollment of its Phase 2a clinical trial of PRX-03140 in Alzheimer’s disease and reaffirmed that it is on track to announce the findings of this study by the end of 2007.
